Engineering Antibodies

Abstract

Monoclonal antibodies have emerged as a leading class of
therapeutic interventions in the last two decades, particularly for cancer
and autoimmune disorders. A number of inventions and improvements
including the hybridoma technique and recombinant DNA technology
have been instrumental behind the development of recombinant antibodies
that have made the commercial production viable. Antibody
engineering efforts have resulted in many newer formats like Fab and
scFv fragments, Fc-fusion proteins and bispecific antibodies leading to
T cell engagers entering the clinical practice. This review explores the
engineered antibody landscape, beginning with a historical perspective
of technology development, leading to antibodies in current clinical
practice, and finally providing a perspective on the future of antibody
therapeutics.